ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.1827del (p.Arg608_Tyr609insTer) (rs781088002)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel, ClinGen RCV000169308 SCV001371738 pathogenic Glycogen storage disease, type II 2020-02-14 reviewed by expert panel curation This variant, c.1827delC (p.Tyr609Terfs), is a frameshift variant that is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied. This is supported by the absence of cross reactive immunological material studies in cultured fibroblasts from a patient with the variant (PMID 22252923). The highest maximum population minor allele frequency for this variant in gnomAD v2.1.1 is 0.00007181 in the European non-Finnish population. This meets the ClinGen LSD VCEP's threshold for PM2. This variant was found in compound heterozygosity with a unique pathogenic variant in GAA in two patients with Pompe disease who also meet the ClinGen LSD VCEP's specifications for PP4; one of these patients is compound heterozygous for p.Tyr609Terfs and c.2481+102_2646 + 31del, and the other is compound heterozygous for p.Tyr609Terfs and c.-32-13T>G (PMIDs 26693141, 30655185). Therefore, PP4 and PM3 can be applied. Additional cases have been reported but were not included because the residual GAA activity was not provided and therefore PP4 cannot be assessed (PMID 14695532, 30564623). There is a ClinVar entry for this variant (Variation ID: 188936, 2 star review status) with 3 submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3, PP4.
Counsyl RCV000169308 SCV000220630 likely pathogenic Glycogen storage disease, type II 2014-08-25 criteria provided, single submitter literature only
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000726059 SCV000341591 pathogenic not provided 2017-03-13 criteria provided, single submitter clinical testing
Invitae RCV000169308 SCV000827703 pathogenic Glycogen storage disease, type II 2020-07-03 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Tyr609*) in the GAA gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs781088002, ExAC 0.007%). This variant has been reported in combination with another variant in the GAA gene in patients affected with glycogen storage disease (PMID: 14695532, 26693141). ClinVar contains an entry for this variant (Variation ID: 188936). Two additional variants (c.1827C>G and c.1827insA) giving rise to the same protein effect observed here (p.Tyr609*) have been reported in individuals affected with glycogen storage disease (PMID: 12897283, 14695532, 24269976). Loss-of-function variants in GAA are known to be pathogenic (PMID: 2252923, 18425781, 22252923). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000726059 SCV001168492 pathogenic not provided 2018-10-09 criteria provided, single submitter clinical testing The c.1827delC variant in the GAA gene, resulting in the Y609X nonsense variant, has been reported previously in association with both infantile and adult onset glycogen storage disease type II (GSDII) when present with another disease causing variant (Hermans et al., 2004; Bali et al., 2015; Mori et al., 2017). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. In addition, different nucleotide changes (c.1827C>G and c.1826dupA) that also result in the Y609X nonsense variant have been reported in association with GSDII (Hermans et al., 2004; Fu et al., 2014). The c.1827delC variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret c.1827delC as a pathogenic variant.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000169308 SCV001339197 pathogenic Glycogen storage disease, type II 2020-03-10 criteria provided, single submitter clinical testing Variant summary: GAA c.1827delC (p.Tyr609X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 2.9e-05 in 244672 control chromosomes. c.1827delC has been reported in the literature in individuals affected with Glycogen Storage Disease, Type 2 (Pompe Disease) or Limb-girdle muscular dystrophies (e.g. Hermans_2004, Kishnani_2019, Nallamilli_2018). These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Both laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Broad Institute Rare Disease Group, Broad Institute RCV000169308 SCV001422876 pathogenic Glycogen storage disease, type II 2020-01-22 no assertion criteria provided curation The p.Tyr609Ter variant in GAA has been reported in 2 individuals (including 1 Australian individual) with Glycogen Storage Disease II (PMID: 14695532, 26693141), and has also been reported likely pathogenic by Counsyl and pathogenic by EGL in ClinVar (Variation ID: 188936). This variant has been identified in 0.0072% (9/125326) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD,; dbSNP rs781088002). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant leads to a premature termination codon at position 609, which is predicted to lead to a truncated or absent protein. Loss of function of the GAA gene is an established disease mechanism in autosomal recessive Glycogen Storage Disease II. This variant has been seen in combination with a reported pathogenic variant (PMID: 26693141). The phenotype of an individual compound heterozygous for this variant is highly specific for Glycogen Storage Disease II based on low GAA activity consistent with disease (PMID: 26693141). In summary, this variant meets criteria to be classified as pathogenic for Glycogen Storage Disease II in an autosomal recessive manner based on the predicted impact of the variant and the presence of this variant in a patient with a severe deficiency in GAA activity. ACMG/AMP Criteria applied: PVS1, PP4, PM2 (Richards 2015).
Natera, Inc. RCV000169308 SCV001459736 pathogenic Glycogen storage disease, type II 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.